Desvenlafaxine in the treatment of major depressive disorder

Código QR

Desvenlafaxine in the treatment of major depressive disorder

Maria Teresa C Lourenco1, Sidney H Kennedy1,21Department of Psychiatry, University Health Network, Toronto; 2Department of Psychiatry, University of Toronto, Toronto, CanadaAbstract: Major depressive disorder (MDD) is among the most incapacitating conditions in the world. The emergence of the select...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Teresa C Lourenco1, Sidney H Kennedy1,2
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/8043b3d2f9754bdfbcbd3a07a856cddc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Mazen K Ali, et al.
Publicado: (2011)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: J Craig Nelson, et al.
Publicado: (2008)

Levomilnacipran for the treatment of major depressive disorder: a review
por: Asnis GA, et al.
Publicado: (2015)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez E, et al.
Publicado: (2014)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
por: Aoki A, et al.
Publicado: (2014)

Psychiatric comorbidities in patients with major depressive disorder
por: Thaipisuttikul P, et al.
Publicado: (2014)

Mitochondrial dysfunction, oxidative stress, and major depressive disorder
por: Tobe EH
Publicado: (2013)

Drug–drug interactions involving antidepressants: focus on desvenlafaxine
por: Low Y, et al.
Publicado: (2018)

Major depressive disorder: mechanism-based prescribing for personalized medicine
por: Saltiel PF, et al.
Publicado: (2015)

Anatomical and functional brain abnormalities in unmedicated major depressive disorder
por: Yang X, et al.
Publicado: (2015)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang XF, et al.
Publicado: (2015)

Transcranial magnetic stimulation for the treatment of major depression
por: Janicak PG, et al.
Publicado: (2015)

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
por: Kitaichi Y, et al.
Publicado: (2013)

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh M, et al.
Publicado: (2012)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Bernhard T Baune
Publicado: (2008)

Major depressive disorders in chronic hemodialysis patients in Nazareth: identification and assessment
por: Armaly Z, et al.
Publicado: (2012)

Getting the balance right: Established and emerging therapies for major depressive disorders
por: Bojana Perovic, et al.
Publicado: (2010)

Is placebo useful in the treatment of major depression in clinical practice?
por: Marchesi C, et al.
Publicado: (2013)

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
por: Marty Hinz, et al.
Publicado: (2010)

A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder
por: Baskaran A, et al.
Publicado: (2013)

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
por: Han Y, et al.
Publicado: (2016)

Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: a pilot study
por: Fontani V, et al.
Publicado: (2011)

Association between toll-like receptor 4 expression and symptoms of major depressive disorder
por: Wu MK, et al.
Publicado: (2015)

Neutrophil–lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy
por: Demir S, et al.
Publicado: (2015)

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
por: Novick D, et al.
Publicado: (2015)

Impact of dissociation on treatment of depressive and anxiety spectrum disorders with and without personality disorders
por: Prasko J, et al.
Publicado: (2016)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman R, et al.
Publicado: (2011)

Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population
por: Kawamura S,&nbsp;Maesawa C,&nbsp;Nakamura K,&nbsp;Nakayama K,&nbsp;Morita M,&nbsp;Hiruma Y,&nbsp;Yoshida T,&nbsp;Sakai A,&nbsp;Masuda T
Publicado: (2011)

Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study
por: Gabriel A
Publicado: (2013)

The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients
por: Koshino Y, et al.
Publicado: (2013)

Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
por: Michele Fornaro, et al.
Publicado: (2011)

Increased expression of retinoic acid-induced gene 1 in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression
por: Haybaeck J, et al.
Publicado: (2015)

Case-control association study of ABCB1 gene and major depressive disorder in a local Chinese Han population
por: Xie WW, et al.
Publicado: (2015)

Twelve-month, prospective, open-label study of repetitive transcranial magnetic stimulation for major depressive disorder in partial remission
por: Charnsil C, et al.
Publicado: (2012)

The structural equation analysis of childhood abuse, adult stressful life events, and temperaments in major depressive disorders and their influence on refractoriness
por: Toda H, et al.
Publicado: (2015)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton B, et al.
Publicado: (2018)

The predictive value of somatic and cognitive depressive symptoms for cytokine changes in patients with major depression
por: Dannehl K, et al.
Publicado: (2014)

The cortisol awakening response and major depression: examining the evidence
por: Dedovic K, et al.
Publicado: (2015)

Psychomotor retardation and externally oriented thinking in major depression
por: Luca M, et al.
Publicado: (2013)

Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
por: Robert H Howland
Publicado: (2009)